Changes After Suprachoroidal Injection.

NCT ID: NCT05288192

Last Updated: 2022-03-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-15

Study Completion Date

2022-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Changes after suprachoroidal injection are analyzed for statistical analysis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Changes after suprachoroidal injection of triamcinolone acetonide are noted in various retinal diseases treated by this technique to address its effects over six months of follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Retina; Change Intraocular Pressure Cataract Macular Edema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Suprachoroidal triamcinolone injection

Eyes treated with suprachoroidal injection of triamcinolone acetonide.

Group Type ACTIVE_COMPARATOR

Suprachoroidal triamcinolone acetonide (SCTA) injection

Intervention Type DRUG

Suprachoroidal injection of 4mg/0.1ml of triamcinolone acetonide.

Non-treated eyes

Eyes that are receiving no interventions during the study period.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Suprachoroidal triamcinolone acetonide (SCTA) injection

Suprachoroidal injection of 4mg/0.1ml of triamcinolone acetonide.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SCTA injection

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients prepared to suprachoroidal injection for various retinal diseases will be enrolled in the study.
* Bilateral retinal diseases that required interventions as diabetic macular edema, exudative retinal detachment, and serous chorioretinopathies.

Exclusion Criteria

* Other retinal diseases that are not expected to improve after steroid injections as central retinal artery occlusion and age-related macular degenerations.
* Choroidal neovascularization that require anti-vascular endothelial growth factors.
* Patients refused to have steroid injections even after discussing the nature of their disease with them and the procedure to be done.
Minimum Eligible Age

30 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Benha University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ahmed Abdelshafy

Lecturer of Ophthalmology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ahmed A Tabl, MD

Role: PRINCIPAL_INVESTIGATOR

Benha University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Benha University

Banhā, QA, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ahmed Abdelshafy

Role: CONTACT

01222328766

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ahmed Abdelshafy, MD

Role: primary

01222328766

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Rc-3-22

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.